- Cat. No.
- A13721
(E/Z)-TG003
Synonyms: TG-003
(E/Z)-TG003 is a potent, specific, reversible, and ATP competitive inhibitor of Cdc2 like kinase(Clk).-
In stock
View Details
-
-
- Cat. No.
- A14297
ML167
Synonyms: CID 44968231
ML167 is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor
In stock View Details -
- Cat. No.
- A16995
CC-671
CC-671 is a potent and selective dual inhibitor of TTK (Mps1) and CLK2.
In stock View Details -
- Cat. No.
- A19750
CLK1-IN-1
CLK1-IN-1 is a potent and selective of Cdc2-like kinase 1 (CLK1) inhibitor, with an IC50 of 2 nM.
In stock View Details -
- Cat. No.
- A30188
T025
T025 is a potent and orally active inhibitor of Cdc2-like kinases (CLKs), exhibiting Kd values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5, and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B, and DYRK2, respectively. This compound induces apoptosis through caspase-3/7 activation and effectively reduces CLK-dependent phosphorylation. T025 demonstrates significant anti-proliferative activity in hematological and solid tumor cell lines, with IC50 values ranging from 30 to 300 nM, making it particularly relevant for MYC-driven cancer research applications.
In stock View Details -
- Cat. No.
- A35046
CLK-IN-T3
CLK-IN-T3 is a highly potent and selective inhibitor of CDC-like kinases (CLKs), exhibiting IC50 values of 0.67 nM for CLK1, 15 nM for CLK2, and 110 nM for CLK3. This compound demonstrates significant anti-cancer activity, making it a valuable tool for research applications focused on cancer biology and the modulation of spliceosome activity. Its specificity for CLK isoforms allows for targeted studies in kinase signaling pathways and therapeutic interventions.
In stock View Details -
- Cat. No.
- A35062
Leucettinib-92
Leucettinib-92 is a selective inhibitor of DYRK and CLK kinases, demonstrating IC50 values of 147 nM for CLK1, 39 nM for CLK2, 5.2 nM for CLK4, and 124 nM for DYRK1A, among others. This compound exhibits significant biological activity by modulating kinase signaling pathways, making it a valuable tool for research in oncology and neurodegenerative diseases. Its potency against key kinases provides potential insights into therapeutic targeting and intervention strategies in various cellular processes.
In stock View Details -
- Cat. No.
- A35064
CLK1-IN-3
CLK1-IN-3 is a potent and selective inhibitor of CLK1, exhibiting an IC50 value of 5 nM and demonstrating over 300-fold selectivity for DYRK1A. Additionally, it shows significant inhibitory effects on CLK2 and CLK4, with IC50 values of 42 nM and 108 nM, respectively. CLK1-IN-3 effectively induces autophagy in vitro and serves as a valuable tool for research related to acute liver injury (ALI).
In stock View Details -
- Cat. No.
- A35071
KH-CB20
KH-CB20 is a selective inhibitor of CLK1 and CLK4, demonstrating potent activity with an IC50 of 16.5 nM for CLK1. Additionally, KH-CB20 exhibits inhibition of DYRK1A with an IC50 of 57.8 nM, as well as CLK3 at an IC50 of 488 nM. This compound is valuable for research applications focused on exploring the roles of CLK kinases in cellular processes and disease mechanisms.
In stock View Details -
- Cat. No.
- A35084
KuWal151
KuWal151 is a selective inhibitor of CLK1, CLK2, and CLK4 kinases, demonstrating a significant preference for DYRK kinases. This compound exhibits potent antiproliferative effects across various cultured cancer cell lines, making it a valuable tool for cancer research. Its mechanism of action may provide insights into the role of cyclin-dependent kinases in tumorigenesis and therapeutic resistance. KuWal151 is suitable for studies focused on cancer biology and drug development targeting kinase pathways.
In stock View Details -
- Cat. No.
- A44180
Ipivivint
Ipivivint is a potent orally active inhibitor of CDC-like kinases (CLKs), demonstrating an EC50 of 1 nM for CLK2 and 7 nM for CLK3 in human studies. Additionally, it effectively inhibits the Wnt signaling pathway with an EC50 of 13 nM and tyrosine phosphorylation-regulated kinase 1A (TPRK1A) at an EC50 of 5 nM. This compound is valuable for research applications focused on CLKs and related signaling pathways, contributing to the understanding of various biological processes and potential therapeutic targets.
In stock View Details -
- Cat. No.
- A54127
Cirtuvivint
Synonyms: SM08502
Cirtuvivint is a potent inhibitor of CDC-like kinases (CLK), exhibiting oral bioavailability. This compound demonstrates significant potential in the modulation of pre-mRNA splicing, which is crucial for understanding various solid tumors. Cirtuvivint is suitable for research focused on cancer biology and therapeutic development targeting CLK pathways.
In stock View Details -
- Cat. No.
- A54133
Rogocekib
Synonyms: CTX-712
Rogocekib is a potent CLK2 inhibitor, exhibiting an IC50 of 1.4 nM. This compound demonstrates significant anti-tumor activity, making it valuable for cancer research. Its ability to selectively inhibit CLK2 positions Rogocekib as an important tool for investigating the role of clock proteins in various malignancies and potential therapeutic interventions.
In stock View Details -
- Cat. No.
- A54140
CLK1-IN-2
CLK1-IN-2 is a potent and metabolically stable inhibitor of CLK1, exhibiting a selectivity for its target with an IC50 value of 1.7 nM. This compound is valuable for research applications focusing on tumor biology, Duchenne muscular dystrophy, and viral infections, including HIV-1 and influenza. CLK1-IN-2 facilitates the study of cellular mechanisms and therapeutic interventions related to these diseases.
In stock View Details -
- Cat. No.
- A54142
KH-CB19
KH-CB19 is a selective inhibitor of CLK (cdc2-like kinase) with an IC50 of 19.7 nM for CLK1 and 530 nM for CLK3. This compound exhibits antiviral properties, demonstrated by its ability to hinder influenza virus replication, with an IC50 value of 13.6 μM. KH-CB19 serves as a valuable tool for research into CLK-related pathways and antiviral drug development.
In stock View Details -
- Cat. No.
- A54153
SGC-CLK-1
Synonyms: CAF-170
SGC-CLK-1 is a potent and selective inhibitor of Cdc2-like kinases CLK1, CLK2, and CLK4. This compound exhibits significant anti-proliferative activity against melanoma and glioblastoma cell lines. It serves as a valuable tool for investigating the roles of these kinases in various biological processes and may aid in therapeutic development for related cancers.
In stock View Details -
- Cat. No.
- A54166
SRI-29329
SRI-29329 is a selective CLK inhibitor, demonstrated to effectively inhibit CLK1, CLK2, and CLK4 with IC50 values of 78 nM, 16 nM, and 86 nM, respectively. This compound is valuable for research into the regulation of pre-mRNA splicing and circadian rhythms, offering potential insights into various biological processes and diseases. Its specificity allows for targeted studies in the modulation of clock gene expression and related therapeutic applications.
In stock View Details -
- Cat. No.
- A54221
TG693
TG693 is an orally active inhibitor of Clock-Like Protein 1 (CLK1), targeting its enzymatic function in splicing regulation. By modulating the mutated exon 31 of the dystrophin gene, TG693 shows potential in the treatment of Duchenne muscular dystrophy (DMD). This reagent is useful for research applications focused on understanding and addressing the molecular mechanisms underlying DMD.
In stock View Details -
- Cat. No.
- A54229
CLK1/2-IN-1
CLK1/2-IN-1 is a selective inhibitor of CLK1 and CLK2, demonstrating IC50 values of 16 nM and 45 nM, respectively. This compound exhibits significant anti-cancer activity, making it a valuable tool for research in cancer biology and therapeutic development. Its ability to modulate spliceosomal activities positions CLK1/2-IN-1 as an effective agent for exploring the regulatory mechanisms of gene expression in tumorigenesis.
In stock View Details -
- Cat. No.
- A54230
DB18
DB18 is a potent and selective inhibitor of CDC2-like kinases (CLKs), demonstrating IC50 values between 10-30 nM for CLK1, CLK2, and CLK4. This compound exhibits anti-tumor activity, making it valuable for research applications aimed at understanding cancer biology and therapeutic interventions targeting CLK-mediated signaling pathways.
In stock View Details -
- Cat. No.
- A54246
CLK1-IN-4
CLK1-IN-4 is a selective inhibitor of CDC-like kinase 1 (CLK-1) with an IC50 value of 2.5 μM. This compound modulates alternative splicing by inhibiting CLK-1, making it a valuable tool for studies investigating the regulation of gene expression and the functional implications of splicing variation. CLK1-IN-4 is applicable in research related to cancer biology and other diseases where splicing dysregulation plays a significant role.
In stock View Details -
- Cat. No.
- A54316
CLK1/4-IN-1
CLK1/4-IN-1 is a selective inhibitor of CLK1 and CLK4, displaying IC50 values of 9.7 nM and 6.6 nM, respectively. This compound demonstrates significant growth inhibitory activity against T24 cancer cells, with a GI50 of 1.1 μM. CLK1/4-IN-1 is suitable for research focused on anticancer therapies and the exploration of CLK-related signaling pathways in cancer biology.
Out of stock
All 3 sizes -
- Cat. No.
- A54333
Indazole 1
Indazole 1 is a potent inhibitor of CDC2-like kinase 2 (CLK2), exhibiting an IC50 value of 12.3 nM. This compound effectively inhibits the phosphorylation of serine/arginine-rich (SR) proteins, such as SRSF1 and SRSF3, thereby modulating alternative splicing of genes associated with Wnt signaling pathways. Indazole 1 holds potential for research applications in understanding osteoarthritis and related molecular mechanisms.
Out of stock
All 3 sizes -
- Cat. No.
- A54361
CLK1/4-IN-2
CLK1/4-IN-2 is a selective inhibitor of CLK1 and CLK4, demonstrating an IC50 of 7 nM and 2.3 nM, respectively. This compound induces protein depletion in cancer cells, exhibiting potent anticancer activity. CLK1/4-IN-2 is applicable for research in various cancer types, including breast cancer, monocytic leukemia, bladder cancer, mammary adenocarcinoma, and hepatocellular carcinoma.
Out of stock
All 3 sizes -
- Cat. No.
- A54394
CLK1/2-IN-3
CLK1/2-IN-3 is a potent and selective inhibitor of CLK1 and CLK2, exhibiting IC50 values of 1.1 nM and 2.1 nM, respectively. This compound demonstrates significant anti-proliferative activity and effectively decreases the levels of endogenous phosphorylated SR proteins. In addition, CLK1/2-IN-3 enhances the expression of S6K mRNAs, making it a valuable tool for research applications focused on alternative splicing regulation and cellular signaling pathways.
In stock View Details